The EGR2 gene is involved in axonal Charcot-Marie-Tooth disease

[EN] Background and purpose: A three-generation family affected by axonal Charcot-Marie-Tooth disease (CMT) was investigated with the aim of discovering genetic defects and to further characterize the phenotype. Methods: The clinical, nerve conduction studies and muscle magnetic resonance images of the patients were reviewed. A whole exome sequencing was performed and the changes were investigated by genetic studies, in silico analysis and luciferase reporter assays. Results: A novel c.1226G>A change (p.R409Q) in the EGR2 gene was identified. Patients presented with a typical, late-onset axonal CMT phenotype with variable severity that was confirmed in the ancillary tests. The in silico studies showed that the residue R409 is an evolutionary conserved amino acid. The p.R409Q mutation, which is predicted as probably damaging, would alter the conformation of the protein slightly and would cause a decrease of gene expression. Conclusions: This is the first report of an EGR2 mutation presenting as an axonal CMT phenotype with variable severity. This study broadens the phenotype of the EGR2-related neuropathies and suggests that the genetic testing of patients suffering from axonal CMT should include the EGR2 gene.This collaborative joint project is awarded by IRDiRC and funded by the Instituto de Salud Carlos III (ISCIII) - Subdireccion General de Evaluacion y Fomento de la Investigacion within the framework of the National R+D+I Plan (Grants IR11/TREAT-CMT, PI12/00946 and PI12/00453), co-funded with FEDER funds. C.E. has a "Miguel Servet' contract funded by the ISCIII and Centro de Investigacion Principe Felipe (CIPF) (Grant no. CPII14/00002). We are also grateful to Itziar Llopis for sample management.Sevilla, T.; Sivera, R.; Martínez-Rubio, D.; Lupo, V.; Chumillas, M.; Calpena-Corpas, E.; Dopazo, J.... (2015). The EGR2 gene is involved in axonal Charcot-Marie-Tooth disease. European Journal of Neurology. 22(12):1548-1555. https://doi.org/10.1111/ene.1278215481555221

CIBERER : Spanish national network for research on rare diseases: A highly productive collaborative initiative

Altres ajuts: Instituto de Salud Carlos III (ISCIII); Ministerio de Ciencia e Innovación.CIBER (Center for Biomedical Network Research; Centro de Investigación Biomédica En Red) is a public national consortium created in 2006 under the umbrella of the Spanish National Institute of Health Carlos III (ISCIII). This innovative research structure comprises 11 different specific areas dedicated to the main public health priorities in the National Health System. CIBERER, the thematic area of CIBER focused on rare diseases (RDs) currently consists of 75 research groups belonging to universities, research centers, and hospitals of the entire country. CIBERER's mission is to be a center prioritizing and favoring collaboration and cooperation between biomedical and clinical research groups, with special emphasis on the aspects of genetic, molecular, biochemical, and cellular research of RDs. This research is the basis for providing new tools for the diagnosis and therapy of low-prevalence diseases, in line with the International Rare Diseases Research Consortium (IRDiRC) objectives, thus favoring translational research between the scientific environment of the laboratory and the clinical setting of health centers. In this article, we intend to review CIBERER's 15-year journey and summarize the main results obtained in terms of internationalization, scientific production, contributions toward the discovery of new therapies and novel genes associated to diseases, cooperation with patients' associations and many other topics related to RD research

Les chironomidés (Diptera) du bassin du Haut-Guadalquivir (Sierra de Cazorla, sud de l'Espagne)

Des exuvies nymphales, des nymphes et des imagos de Chironomidés ont été récoltés par dérive ou par des chasses en vol dans 17 stations du cours supérieur du Guadalquivir (Andalousie) en 1987 et 1988. Les stations sont échelonnées entre 240 m et 1330 m d'altitude. Sur 165 espèces recensées, 86 sont nouvelles pour le Guadalquivir et 21 pour l'Espagne. 4 nouvelles exuvies ont été récoltées. Ce travail porte à 376 le total des espèces actuellement connues dans la Péninsule Ibérique. 26 % des espèces ont une distribution holarctique, 70 % sont paléarctiques, dont 46 % avec une large répartition; 5 % sont méditerranéennes, 1 % a une distribution afrotropicale et 3 % sont présentes dans plusieurs régions biogéographiques. La composition faunistique est très semblable à celle des Pyrénées et du Massif Central français. La différence est plus importante avec celle de la Sierra Nevada, pourtant plus proche, de par les différentes conditions hydrologiques et physiographiques de ces deux régions. La similitude faunistique avec des rivières marocaines du Rif et du Haut-Atlas est plus faible

Guía diagnóstica en el paciente con enfermedad de Charcot-Marie-Tooth

Resumen: Introducción: La enfermedad de Charcot-Marie-Tooth (CMT) es la neuropatía hereditaria más frecuente. Clásicamente dividida según su patrón de herencia y de alteración de la velocidad de conducción motora (VCM) del nervio mediano, CMT incluye cinco grandes categorías: CMT1 (herencia autosómica dominante [AD] o ligada al sexo, y VCM 38 m/s); CMT4 (herencia autosómica recesiva [AR] y VCM muy lentificada); AR-CMT2 (forma recesiva con VCM > 38 m/s), y DI-CMT (forma intermedia con herencia AD y VCM entre 30 y 40 m/s). Pese a su estereotipado cuadro clínico (básicamente, semiología polineuropática sensitivo-motora y pie cavo), CMT ha resultado ser uno de los síndromes neurodegenerativos genéticamente más complejos, con 31 genes patogénicos clonados. Desarrollo: El objetivo de esta guía es efectuar una revisión nosológica de la enfermedad de CMT, con énfasis en las directrices para llevar a cabo el diagnóstico molecular. A tal fin, revisamos los estudios de epidemiología y genética, y los genotipos descritos en España. Conclusiones: En la inmensa mayoría de los pacientes con CMT, las mutaciones recaen en un reducido número de genes: para CMT1, PMP22, GJB1 y MPZ; para CMT2, MFN2 y GJB1; para CMT4, GDAP1, y NDRG1, HK1 y SH3TC2 (sujetos de etnia gitana); para AR-CMT2, GDAP1, y para DI-CMT, GJB1 y MPZ. Por su baja prevalencia, las mutaciones en otros genes sólo deberían investigarse cuando las anteriores han sido descartadas. Se desaconseja el uso indiscriminado de paneles de múltiples genes para el diagnóstico molecular de la enfermedad. Abstract: Introduction: Charcot-Marie-Tooth disease (CMT) is the most frequent form of inherited neuropathy. In accordance with the inheritance pattern and degree of slowing of motor conduction velocity (MCV) of the median nerve, CMT encompasses five main forms: CMT1 (autosomal dominant [AD] or X-linked transmission and MCV 38 m/s); CMT4 (autosomal recessive [AR] and severe slowing of MCV); AR-CMT2 (AR transmission and MCV > 38 m/s); and DI-CMT (intermediate form with AD transmission and MCV between 30 and 40 m/s). In spite of its stereotyped semiological repertoire (basically, symptoms and signs of sensory-motor polyneuropathy and pes cavus), CMT seems to be one of the most complex hereditary neurodegenerative syndromes, 31 causative genes having been cloned. Development: This paper is aimed at performing a nosological review of the disease, emphasising the guidelines for its molecular diagnosis. Genetic epidemiological studies and genotypes reported in Spanish patients are revised. Conclusions: In the great majority of CMT cases, mutations involve a reduced number of genes, namely: for CMT1, PMP22, GJB1 and MPZ; for CMT2, MFN2 and GJB1; for CMT4, GDAP1, and NDRG1, HK1 and SH3TC2 (gypsies); for AR-CMT2, GDAP1; and for DI-CMT, GJB1 and MPZ. Given their low prevalence, mutations in other pathogenic genes should be investigated after discarding the previous ones. There is no place for the indiscriminate use of diagnostic CMT genetic panels. Palabras clave: Axón, Consejo genético, Diagnóstico molecular, Enfermedad de Charcot-Marie-Tooth, Enfermedad de Dejerine-Sottas, Guía clínica, Mielina, Mutación génica, Neuropatía genética, Velocidad de conducción motora de nervio, Keywords: Axon, Charcot-Marie-Tooth disease, Clinical guideline, Dejerine-Sottas disease, Genetic counselling, Gene mutation, Genetic neuropathy, Molecular diagnosis, Myelin, Motor nerve conduction velocit

Characterization of pulmonary function in 10–18 year old patients with Duchenne muscular dystrophy

Pulmonary function loss in patients with Duchenne muscular dystrophy (DMD) is progressive and leads to pulmonary insufficiency. The purpose of this study in 10â18 year old patients with DMD is the assessment of the inter-correlation between pulmonary function tests (PFTs), their reliability and the association with the general disease stage measured by the Brooke score. Dynamic PFTs (peak expiratory flow [PEF], forced vital capacity [FVC], forced expiratory volume in one second [FEV1]) and maximum static airway pressures (MIP, MEP) were prospectively collected from 64 DMD patients enrolled in the DELOS trial (ClinicalTrials.gov, number NCT01027884). Baseline PEF percent predicted (PEF%p) was <80% and patients had stopped taking glucocorticoids at least 12 months prior to study start. At baseline PEF%p, FVC%p and FEV1%p correlated well with each other (Spearman's rho: PEF%pâFVC%p: 0.54; PEF%pâFEV1%p: 0.72; FVC%pâFEV1%p: 0.91). MIP%p and MEP%p correlated well with one another (MIP%pâMEP%p: 0.71) but less well with PEF%p (MIP%pâPEF%p: 0.40; MEP%pâPEF%p: 0.41) and slightly better with FVC%p (MIP%pâFVC%p: 0.59; MEP%pâFVC%p: 0.74). The within-subject coefficients of variation (CV) for successive measures were 6.97% for PEF%p, 6.69% for FVC%p and 11.11% for FEV1%p, indicating that these parameters could be more reliably assessed compared to maximum static airway pressures (CV for MIP%p: 18.00%; MEP%p: 15.73%). Yearly rates of PFT decline (placebo group) were larger in dynamic parameters (PEF%p: â8.9% [SD 2.0]; FVC%p: â8.7% [SD 1.1]; FEV1%p: â10.2% [SD 2.0]) than static airway pressures (MIP%p: â4.5 [SD 1.3]; MEP%p: â2.8 [SD 1.1]). A considerable drop in dynamic pulmonary function parameters was associated with loss of upper limb function (transition from Brooke score category 4 to category 5). In conclusion, these findings expand the understanding of the reliability, correlation and evolution of different pulmonary function measures in DMD patients who are in the pulmonary function decline phase

Idebenone reduces respiratory complications in patients with Duchenne muscular dystrophy

AbstractIn Duchenne muscular dystrophy (DMD), progressive loss of respiratory function leads to restrictive pulmonary disease and places patients at significant risk for severe respiratory complications. Of particular concern are ineffective cough, secretion retention and recurrent respiratory tract infections. In a Phase 3 randomized controlled study (DMD Long-term Idebenone Study, DELOS) in DMD patients 10–18 years of age and not taking concomitant glucocorticoid steroids, idebenone (900 mg/day) reduced significantly the loss of respiratory function over a 1-year study period. In a post-hoc analysis of DELOS we found that more patients in the placebo group compared to the idebenone group experienced bronchopulmonary adverse events (BAEs): placebo: 17 of 33 patients, 28 events; idebenone: 6 of 31 patients, 7 events. The hazard ratios (HR) calculated “by patient” (HR 0.33, p = 0.0187) and for “all BAEs” (HR 0.28, p = 0.0026) indicated a clear idebenone treatment effect. The overall duration of BAEs was 222 days (placebo) vs. 82 days (idebenone). In addition, there was also a difference in the use of systemic antibiotics utilized for the treatment of BAEs. In the placebo group, 13 patients (39.4%) reported 17 episodes of antibiotic use compared to 7 patients (22.6%) reporting 8 episodes of antibiotic use in the idebenone group. Furthermore, patients in the placebo group used systemic antibiotics for longer (105 days) compared to patients in the idebenone group (65 days). This post-hoc analysis of DELOS indicates that the protective effect of idebenone on respiratory function is associated with a reduced risk of bronchopulmonary complications and a reduced need for systemic antibiotics

The miniJPAS survey: a preview of the Universe in 56 colours

International audienceThe Javalambre-Physics of the Accelerating Universe Astrophysical Survey (J-PAS) will soon start to scan thousands of square degrees of the northern extragalactic sky with a unique set of $56$ optical filters from a dedicated $2.55$m telescope, JST, at the Javalambre Astrophysical Observatory. Before the arrival of the final instrument (a 1.2 Gpixels, 4.2deg$^2$ field-of-view camera), the JST was equipped with an interim camera (JPAS-Pathfinder), composed of one CCD with a 0.3deg$^2$ field-of-view and resolution of 0.23 arcsec pixel$^{-1}$. To demonstrate the scientific potential of J-PAS, with the JPAS-Pathfinder camera we carried out a survey on the AEGIS field (along the Extended Groth Strip), dubbed miniJPAS. We observed a total of $\sim 1$ deg$^2$, with the $56$ J-PAS filters, which include $54$ narrow band (NB, $\rm{FWHM} \sim 145$Angstrom) and two broader filters extending to the UV and the near-infrared, complemented by the $u,g,r,i$ SDSS broad band (BB) filters. In this paper we present the miniJPAS data set, the details of the catalogues and data access, and illustrate the scientific potential of our multi-band data. The data surpass the target depths originally planned for J-PAS, reaching $\rm{mag}_{\rm {AB}}$ between $\sim 22$ and $23.5$ for the NB filters and up to $24$ for the BB filters ($5\sigma$ in a $3$~arcsec aperture). The miniJPAS primary catalogue contains more than $64,000$ sources extracted in the $r$ detection band with forced photometry in all other bands. We estimate the catalogue to be complete up to $r=23.6$ for point-like sources and up to $r=22.7$ for extended sources. Photometric redshifts reach subpercent precision for all sources up to $r=22.5$, and a precision of $\sim 0.3$% for about half of the sample. (Abridged